Subcutaneous administration of interferon alpha and gamma in XXXX with @entity1358 .

@entity1 @entity1358 @entity379 @entity14584 @entity3027
BACKGROUND: @entity1358 ( @entity1358 ) is relatively resistant to both chemotherapy and radiotherapy. Response and survival of treatment with @entity14584 -alpha ( @entity3027 ) and @entity379 ( @entity379 ) were evaluated in @entity1 with metastatic @entity1358 . @entity1 AND METHODS: Thirty-one @entity1 with confirmed @entity1358 were included in this study. Fifteen of 31 @entity1 received injection of @entity3027 and @entity379 three times a week. @entity379 was infused subcutaneously by microinfusion pump. Sixteen received @entity3027 alone more than three times a week. RESULTS: The overall response rate was 20.0% in the @entity3027 and @entity379 group, and 12.5% in the @entity3027 alone group. Long lasting stabilization of the disease (more than; 12 months) was seen in 92.3% of CR, PR or SD in the @entity3027 and @entity379 group, as compared with 71.4% in the @entity3027 alone group. Both groups differed significantly in survival rate from the first treatment with IFN (p < 0.05). CONCLUSIONS: A long lasting stabilization of the disease can be expected in @entity1 who were treated with our regimen of @entity3027 and @entity379 .
